Presentations

«Go Back

EHA2021 - HALF-LIFE PROLONGATION OF VON WILLEBRAND FACTOR:
A new therapeutic strategy for haemophilia A and von Willebrand Disease

Katarina Kovacevic, PhD, Department of Clinical Pharmacology, Medical University of Vienna, 11.06.2021.

Contact

© 2023 Guardian Therapeutics. All rights reserved.

Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com